Ph.D. from Ohio State University, completed in 1978
As of 1978 · Last known relationship
Richard Ellsworth Pratt is a cardiovascular researcher whose documented portfolio spans renin biology, cardiac regeneration, and emerging cardiac reprogramming strategies. He earned a Ph.D. from Ohio State University in 1978 and is listed as a Visiting Associate Professor in Duke’s Department of Medicine. His NIH-supported work has examined renin gene expression and cardiovascular regulation, mesenchymal stem cells and neovascularization, Sfrp2 and cardiac progenitor-cell differentiation, and microRNA-based approaches to regeneration. A 2025 to 2029 National Heart, Lung, and Blood Institute grant addresses cardiac reprogramming through exosome delivery of reprogramming microRNAs and repressor-targeting siRNAs. He has also been identified as a collaborator on smart gene therapy research concerning cardiac injury.
Each topic is linked to its supporting source in Sources.
Training includes Ph.D. from Ohio State University, completed in 1978 and Visiting Associate Professor in the Department of Medicine at Duke.
Explore education and trainingCo-investigator on the NIH-funded grant Renin Gene Expression in Cardiovascular Regulation: Mechanisms of JG Hyperplasia[5]
1985 to 2013
Collaborator on research concerning smart gene therapy and cardiac injury, with Brigham and Women's Hospital[6]
Research grant on enhancing miRNA as a therapeutic for cardiac regeneration[4]
2016 to 2020
Research grant on genetically altered mesenchymal stem cells and their paracrine effect on neovascularization[4]
2003 to 2014
Research grant on novel approaches for cardiac reprogramming using exosome delivery of reprogramming miRNAs and repressor targeting siRNAs[4]
2025 to 2029
Research grant on renin gene expression in cardiovascular regulation and mechanisms of JG hyperplasia[4]
1985 to 2013
Research grant on Sfrp2 and cardiac progenitor cells in regenerative response to ischemic injury[4]
2005 to 2016
Research grant on Sfrp2 and cardiac regeneration via c-Kit(+) cell differentiation[4]
2018 to 2022